Drug intelligence / Profile preview

Viaskin-N-FsII

Development stage: Preclinical
Lead developer: DBV Technologies
Administration: Transdermal

Overview

**Viaskin-N-FsII** is an investigational epicutaneous vaccine patch developed using DBV Technologies' proprietary Viaskin platform, incorporating a patented N-FsII antigen from the French National Institute for Agronomical Research (INRA). It delivers the antigen through intact skin to promote a Th1/Th17-oriented immune response, as demonstrated in preclinical studies in mice and swine, aiming to provide protection against respiratory syncytial virus (RSV) infection, particularly in newborns, without needles or skin preparation.[1]

Beyond the preview

Go deeper on Viaskin-N-FsII.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viaskin-N-FsII.

Explore the full profile